Artemether in the treatment of falciparum malaria during pregnancy in eastern Sudan

This study was carried in New Halfa Hospital, eastern Sudan from October 1997 to February 2001. Twenty-eight pregnant Sudanese women infected with Plasmodium falciparum were treated with intramuscular artemether (six injections, 480 mg) after failure of chloroquine and quinine therapy. The patients...

Full description

Saved in:
Bibliographic Details
Published in:Transactions of the Royal Society of Tropical Medicine and Hygiene 2004-09, Vol.98 (9), p.509-513
Main Authors: Adam, Ishag, Elwasila, Eltaib, Mohammed Ali, Daw Alnour, Elansari, Elhassan, Elbashir, Mustafa Idris
Format: Article
Language:English
Subjects:
Adult
Antimalarials - administration & dosage
Artemether
Artemisinins - administration & dosage
Biological and medical sciences
Birth Weight
Falciparum malaria
Female
Human protozoal diseases
Humans
Infectious diseases
Injections, Intramuscular
Malaria
Malaria, Falciparum - drug therapy
Malaria, Falciparum - epidemiology
Medical sciences
Neonates
Parasitic diseases
Pregnancy
Pregnancy Complications, Infectious - drug therapy
Pregnancy Complications, Infectious - epidemiology
Pregnancy Outcome
Protozoal diseases
Sesquiterpenes - administration & dosage
Sudan
Sudan - epidemiology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study was carried in New Halfa Hospital, eastern Sudan from October 1997 to February 2001. Twenty-eight pregnant Sudanese women infected with Plasmodium falciparum were treated with intramuscular artemether (six injections, 480 mg) after failure of chloroquine and quinine therapy. The patients were followed-up until delivery; the babies were followed-up until the age of 1 year. Artemether was given to one patient in the tenth week of gestation, to 12 during the second trimester, and to 15 during the third trimester. It was well tolerated, the parasitaemia was cleared and the patients were symptom-free within three days. One patient (3.5%) delivered at 32 weeks and the baby died six hours after delivery. The other 27 (96.5%) delivered full-term live babies. None of the pregnant women died and there was no abortion, stillbirth or congenital abnormalities in the newborn babies.
ISSN:0035-9203
1878-3503
DOI:10.1016/j.trstmh.2003.11.008